Dr. Michelle E. Melisko

Dr. Michelle E. Melisko, MD, is a prominent medical oncologist specializing in the treatment of breast cancer. She serves as Associate Professor of Medicine in the Division of Hematology and Oncology at the University of California, San Francisco (UCSF), where she is also a key member of the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Melisko earned her medical degree from Wake Forest University School of Medicine and completed her residency in internal medicine at Stanford University, followed by a fellowship in hematology and oncology at UCSF. She has dedicated her career to advancing care for patients with both early-stage and metastatic breast cancer through clinical innovation and patient-centered treatment strategies.

Dr. Melisko’s clinical expertise spans hormone receptor-positive, HER2-positive, and triple-negative breast cancers. She is actively involved in clinical trials focused on novel targeted therapies, immunotherapy, and improving symptom management in breast cancer patients. Her research has contributed to evolving treatment paradigms, particularly in optimizing therapies based on tumor biology and patient-reported outcomes. She has authored numerous peer-reviewed publications and serves as a principal investigator on multiple investigator-initiated and cooperative group studies aimed at improving long-term outcomes and quality of life for individuals living with breast cancer.

Beyond her clinical and research endeavors, Dr. Melisko is deeply committed to mentorship and education. She trains fellows, residents, and medical students through UCSF’s robust academic programs and regularly contributes to national oncology meetings and guideline committees. Board-certified in internal medicine, hematology, and medical oncology, she is highly regarded by colleagues and patients alike for her compassionate, evidence-based approach to care. Through her leadership in clinical research, translational science, and medical education, Dr. Melisko continues to shape the future of breast cancer treatment.